off-the-shelf– tag –
-
REPROCELL Unveils StemEdit Hypoimmune iPSCs with HLA Knockout, Accelerating Development of Off-the-Shelf Cell Therapies
REPROCELL (Blog) Japan Overview REPROCELL has announced the launch of its StemEdit hypoimmune iPSC lines, featuring HLA knockout through high-efficiency genome editing and regulatory-compliant cell lines. This technology aims to mitigate... -
Fate Therapeutics’ Off-the-Shelf iPSC-Derived CAR T-Cell Therapy FT819 Shows Promising Early Clinical Data in Treatment-Resistant Systemic Sclerosis
EurekAlert! USA Overview New preliminary clinical data for Fate Therapeutics' off-the-shelf iPSC-derived CAR T-cell therapy, FT819, was presented at ISSCR 2026, targeting patients with treatment-resistant systemic sclerosis. As part of a... -
Chivanta Analysis: Allogeneic CAR-T Surpasses Autologous in Scalable Manufacturing and Immediate Availability, Spotlighting Fate Therapeutics’ iPSC Platform
Chivanta USA Overview Chivanta's analysis indicates allogeneic CAR-T therapies hold significant advantages over autologous CAR-T, particularly in scalable manufacturing, immediate availability, and product consistency. Companies like All... -
Fate Therapeutics to Announce Preliminary Clinical Data for iPSC-Derived CAR T-Cell FT819 for Systemic Sclerosis at ISSCR 2026
GlobeNewswire USA Overview Fate Therapeutics announced it will present preliminary clinical data for its iPSC-derived 'off-the-shelf' CAR T-cell candidate FT819 for systemic sclerosis (SSc) at the International Society for Stem Cell Rese... -
Fate Therapeutics Receives FDA IND Approval for CAR-T Therapy FT839 for Autoimmune Diseases, Advancing to Phase 1/2 Clinical Trial
GlobeNewswire USA Overview Fate Therapeutics has received U.S. FDA Investigational New Drug (IND) approval for its CAR-T cell therapy candidate, FT839, targeting autoimmune diseases. The company plans to initiate a Phase 1/2 basket clini... -
iPSC-Derived Off-the-Shelf CAR T Therapy FT819 Shows Promising Safety and Efficacy Signals for Treatment-Resistant Systemic Sclerosis at ISSCR 2026
News-Medical.Net - An AZoNetwork Site USA Overview Preliminary clinical data for FT819, an iPSC-derived CAR T-cell therapy targeting treatment-resistant systemic sclerosis, were presented at the ISSCR 2026 Annual Meeting. FT819 is manufa... -
NTHRYS Achieves 40% Cost Reduction in Dual Antigen CAR-T Manufacturing, Offers Off-the-Shelf NK Cell Expansion Services
NTHRYS International Overview NTHRYS has successfully reduced manufacturing costs for dual antigen CAR-T cell scale-up by 40% while accelerating time-to-clinic. Furthermore, the company now offers clinical-grade NK cell expansion and cry... -
Histocell Accelerates Advanced Cell Therapy Production with New 800m² GMP Facility, Targeting 1,200 Annual Batches
REPROCELL Spain Overview Histocell has inaugurated an 800m² Advanced Therapies GMP facility, dramatically increasing its cell manufacturing capacity to an estimated 1,200 batches annually for both autologous and allogeneic treatments. Th... -
Cartherics to File IND for Ovarian Cancer iPSC-Derived NK Cell Therapy CTH-401 After Asia Pacific Award
Cartherics Pty Ltd Australia Overview Australian biotech Cartherics Pty Ltd was recognized as the Emerging Leader in Allogeneic Cell Therapy at the Asia Pacific Cell & Gene Therapy Excellence Awards 2026. Leveraging its proprietary g... -
Gene-Edited iPSC-Derived CAR-T/NK Therapies Target Allogeneic Rejection for Off-the-Shelf Cancer Immunotherapy
MDPI Switzerland Overview Allogeneic T cell therapies represent a scalable, off-the-shelf alternative to autologous approaches, promising to overcome significant logistical and manufacturing limitations. The review highlights iPSC-derive...
